Bruker Selected as ‘Company of the Year’ by Instrument Business Outlook

Rhea-AI Summary

Bruker (BRKR) has been named the Instrument Business Outlook (IBO) 'Company of the Year' for 2023 due to its impressive double-digit organic revenue growth across all major regions and business groups. The company's innovative model, management processes, and disciplined entrepreneurial culture have led to significant portfolio transformation and sustainable growth. Bruker's strategic initiatives like Project Accelerate 2.0 and Operational Excellence position it as a leader in the post-genomic era, with anticipated strong growth for 2024.

BILLERICA, Mass.--(BUSINESS WIRE)-- Bruker Corporation (NASDAQ: BRKR) has been selected as the Instrument Business Outlook (IBO) ‘Company of the Year’ for 2023. IBO cited Bruker’s double-digit organic revenue growth in 2023 in all major regions, and in all business groups, demonstrating a transformed portfolio and operational strength.

The IBO recognition follows Bruker’s three consecutive years of double-digit organic revenue growth. The fast growth can be attributed to the Bruker innovation model, management process and culture of disciplined entrepreneurialism, which have transformed the company’s product portfolio and addressable markets for sustainable above-market growth.

Commenting on the recognition of Bruker as the 2023 winner, Tanya Samazan, editor-in-chief of IBO, said: “We make our annual selection based on the criteria of financial and operational results, new product innovations and notable business developments. This year, Bruker was our standout choice.”

Frank H Laukien, President and CEO of Bruker, commented: “We are very pleased to have been recognized by this respected industry news report in a year when, according to IBO, ‘market conditions proved difficult for the lab tools industry in general.’ Our dual strategy of Project Accelerate 2.0 and Operational Excellence has built our company into an emerging leader in the post-genomic era. As previously stated, for 2024 we again expect excellent growth, with anticipated 8%-10% constant exchange rate (CER) revenue growth, well above-market organic revenue and non-GAAP EPS growth, as foundations for further expansion.”

Tanya Samazan added: “Bruker was the clear choice for our 2023 Company of the Year, not only because of its solid financial performance but also through its range of end markets and diverse product types that allow the company to capitalize on global trends such as clean energy, 3D chips and single cell proteomics. Congratulations to a well-deserving winner.”

IBO is an industry newsletter for the laboratory tools market that delivers the latest business developments, financial data, executive interviews and insight into market trends and opportunities. IBO is a publication of SDi, a division of Science and Medicine Group, which offers custom market research and strategic advisory services.

About Bruker Corporation – Leader of the Post-Genomic Era (Nasdaq: BRKR)

Bruker is enabling scientists and engineers to make breakthrough post-genomic discoveries and develop new applications that improve the quality of human life. Bruker’s high performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity, and customer success in post-genomic life science molecular and cell biology research, in applied and biopharma applications, in microscopy and nanoanalysis, as well as in industrial and cleantech research, and next-gen semiconductor metrology in support of AI. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. For more information, please visit www.bruker.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240401187855/en/

Bruker Investor:

Justin Ward

Sr. Director, Investor Relations & Corporate Development

T: +1 (978) 313-5800

E: Investor.Relations@bruker.com



Bruker Media:

Markus Ziegler

Sr. Director and Head of Group Marketing

T: +49 172 3733531

E: pr@bruker.com

Source: Bruker Corporation

FAQ

Why was Bruker selected as the 'Company of the Year' by IBO?

Bruker was chosen as the 'Company of the Year' by IBO due to its double-digit organic revenue growth in 2023 across all major regions and business groups, reflecting significant portfolio transformation and operational strength.

What factors contributed to Bruker's fast growth according to IBO?

IBO attributed Bruker's fast growth to its innovative model, management processes, and culture of disciplined entrepreneurialism, which have transformed the company's product portfolio and addressable markets for sustainable above-market growth.

What are Bruker's revenue growth expectations for 2024?

Bruker expects 8%-10% constant exchange rate (CER) revenue growth for 2024, well above-market organic revenue and non-GAAP EPS growth, laying foundations for further expansion.